‘BUILDING ONCOLOGY INNOVATIVE ASSETS’

“We are seeing a profitable & sustainable growth momentum across the region & have set an ambitious target of a $1 billion turnover in 2022. A big game changer next year will be the export of MILab products from Indonesia to other emerging markets in Southeast Asia. The goal is to develop MILab into a regional high-value manufacturing hub for both Menarini & our business partners. We are also currently building a tableting facility within MILab, that will be fully operational by 2023. In Singapore, we will continue expanding our R&D capabilities through Menarini Biomarkers, placing emphasis on highly specialised and scientifically valuable fields such as non-invasive prenatal diagnostics. Finally, 2022 is the year we will begin building our next pipeline – oncology innovative assets. Strategic partnerships and inorganic acquisitions remain a focus, as we seek to become the partner of choice to established pharmaceutical players looking to maximise the value and life cycle of their legacy portfolios, as well as startups & MSMEs which have innovative products but minimal, or zero presence in the region. What makes Menarini a reliable partner in one of the world’s largest economies is our capabilities in clinical development support, local registration, as well as a demonstrated track record in quality, pharmacovigilance, & compliance processes, beyond our sales & marketing strengths.”

- MAURIZIO LUONGO, Chief Executive Officer, Menarini Asia-Pacific, Singapore